An interventional study of DNA PCR and Urine Culture in Urinary Tract Infections, sponsored by University Hospitals Cleveland Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by University Hospitals Cleveland Medical Center · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 101st largest by planned enrollment of the 225 interventional ones that give a count, is one of 14 that started in 2025, is one of 94 with no phase, reaches primary completion later than 24 of the 56 other live ones, and was the 243rd registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Megan Bradley · Sites in United States
Ages 65+ · Women only
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
275 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 40
First in 1988; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 136 is close to the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 225 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 275 have an industry lead sponsor. The 10 most frequent:
University Hospitals Cleveland Medical Center is the lead sponsor of 296 studies on the registry; 46 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 30 (83%) have results posted.
University Hospitals Cleveland Medical Center has 2 studies filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 275 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Adults 18 years or older with urinary tract infection (UTI) symptoms. Participants will be assigned to either the urine culture group or the DNA PCR study group by randomization. At time of enrollment in the study they will be also asked to fill out two questionnaires. If prescribed antibiotics for treatment of a UTI, participants will then be called the day after they are scheduled to stop their antibiotics. Participants will be asked to fill out questionnaires the day after finishing antibiotics. Participants will be enrolled in the study for a maximum of 21 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.
Device: DNA PCR
Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.
Diagnostic Test: Urine Culture
Gene analysis with PCR will be conducted from the urine samples of the patients with acute UTI symptoms.
Urine samples of the patients with acute UTI symptoms will be sent to the UH lab for routine urine culture.
Change in symptoms as measured by UTI-SIQ-8 questionnaire
The UTI-SIQ-8 is an eight item questionnaire that asks about symptom severity and symptom impairment on a likert scale from 0 to 4, 0 being not at all and 4 being very strong/very severe.
Time frame: Baseline, one day after antibiotic completion
Change in symptoms as measured by the UTI Symptom Assessment questionnaire
The UTI Symptom Assessment questionnaire is a ten item questionnaire that asks about symptom relief, with lower scores indicating less symptoms.
Time frame: Baseline, one day after antibiotic completion
Length of time from patient presentation to initiation of treatment as measured by medical record review
Time frame: Up to 21 days
Number of antibiotic changes as measured by medical record review
Time frame: Up to 21 days
Duration of antibiotic use as measured by medical record review
Duration will be measured in days
Time frame: Up to 21 days
Number of times participant represents with UTI symptoms as measured by medical record review
Duration will be measured in days
Time frame: Up to 30 days
Number of additional diagnostic procedures related to initial presenting symptoms as measured by medical record review
Time frame: Up to 21 days
Number of hospitalizations related to UTI as measured by medical record review
Time frame: Up to 21 days
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for May 2027, 19 months after the start.
Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's planned 19 months is below that.
Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Sep 2026 → May 2027 and completion Sep 2026 → May 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospitals Cleveland Medical Center →